These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 30334450)

  • 61. EGFR and KRAS Mutations in ALK-Positive Lung Adenocarcinomas: Biological and Clinical Effect.
    Sahnane N; Frattini M; Bernasconi B; Zappa F; Schiavone G; Wannesson L; Antonelli P; Balzarini P; Sessa F; Mazzucchelli L; Tibiletti MG; Martin V
    Clin Lung Cancer; 2016 Jan; 17(1):56-61. PubMed ID: 26381283
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Relevance of molecular alterations in histopathologic subtyping of lung adenocarcinoma based on 2011 International Multidisciplinary Lung Adenocarcinoma Classification].
    Liu B; Shi SS; Wang X; Xu Y; Zhang XH; Yu B; Lu ZF; Wang JD; Zhou XJ
    Zhonghua Bing Li Xue Za Zhi; 2012 Aug; 41(8):505-10. PubMed ID: 23157740
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Somatic mutation analysis of KRAS, BRAF, HER2 and PTEN in EGFR mutation-negative non-small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel deletion in HER2 gene from Indian patients.
    Bhaumik S; Ahmad F; Das BR
    Med Oncol; 2016 Oct; 33(10):117. PubMed ID: 27637917
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Mutational profile of Brazilian lung adenocarcinoma unveils association of EGFR mutations with high Asian ancestry and independent prognostic role of KRAS mutations.
    Leal LF; de Paula FE; De Marchi P; de Souza Viana L; Pinto GDJ; Carlos CD; Berardinelli GN; Miziara JE; da Silva CM; Silva ECA; Pereira R; de Oliveira MA; Scapulatempo-Neto C; Reis RM
    Sci Rep; 2019 Mar; 9(1):3209. PubMed ID: 30824880
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium.
    Steuer CE; Behera M; Berry L; Kim S; Rossi M; Sica G; Owonikoko TK; Johnson BE; Kris MG; Bunn PA; Khuri FR; Garon EB; Ramalingam SS
    Cancer; 2016 Mar; 122(5):766-72. PubMed ID: 26695526
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Family history of lung cancer in never smokers with non-small-cell lung cancer and its association with tumors harboring EGFR mutations.
    Gaughan EM; Cryer SK; Yeap BY; Jackman DM; Costa DB
    Lung Cancer; 2013 Mar; 79(3):193-7. PubMed ID: 23273562
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Targeted Next-Generation Sequencing Reveals Exceptionally High Rates of Molecular Driver Mutations in Never-Smokers With Lung Adenocarcinoma.
    Mack PC; Klein MI; Ayers KL; Zhou X; Guin S; Fink M; Rossi M; Ai-Kateb H; O'Connell T; Hantash FM; Oh WK; Newman S; Schadt EE; Chen R; Hirsch FR
    Oncologist; 2022 Jun; 27(6):476-486. PubMed ID: 35298662
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Imaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK among Treatment-Naïve Patients with Advanced Lung Adenocarcinoma.
    Park J; Kobayashi Y; Urayama KY; Yamaura H; Yatabe Y; Hida T
    PLoS One; 2016; 11(8):e0161081. PubMed ID: 27518729
    [TBL] [Abstract][Full Text] [Related]  

  • 69. No impact of passive smoke on the somatic profile of lung cancers in never-smokers.
    Couraud S; Debieuvre D; Moreau L; Dumont P; Margery J; Quoix E; Duvert B; Cellerin L; Baize N; Taviot B; Coudurier M; Cadranel J; Missy P; Morin F; Mornex JF; Zalcman G; Souquet PJ;
    Eur Respir J; 2015 May; 45(5):1415-25. PubMed ID: 25745045
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [National variation in molecular diagnostics in metastatic lung cancer].
    Kuijpers CCHJ; van den Heuvel MM; Overbeek LIH; van Slooten HJ; van Lindert ASR; Damhuis RAM; Willems SM
    Ned Tijdschr Geneeskd; 2018 Dec; 162():. PubMed ID: 30570921
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Lepidic, Papillary Components and EGFR Mutations are Frequent in Patients With Lung Adenocarcinoma Who are Over 75 Years Old.
    Forest F; Patoir A; Dal-Col P; Da Cruz V; Camy F; Stachowicz ML; Bayle-Bleuez S; Fournel P; Karpathiou G; Péoc'h M
    Appl Immunohistochem Mol Morphol; 2019 Oct; 27(9):667-671. PubMed ID: 30095461
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion.
    Tsai TH; Wu SG; Hsieh MS; Yu CJ; Yang JC; Shih JY
    Lung Cancer; 2015 May; 88(2):208-14. PubMed ID: 25773866
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Analysis of Genetic Alterations in Tunisian Patients with Lung Adenocarcinoma.
    Dhieb D; Belguith I; Capelli L; Chiadini E; Canale M; Bravaccini S; Yangui I; Boudawara O; Jlidi R; Boudawara T; Calistri D; Keskes LA; Ulivi P
    Cells; 2019 May; 8(6):. PubMed ID: 31141932
    [TBL] [Abstract][Full Text] [Related]  

  • 74. High frequency of KRAS and EGFR mutation profiles in BRAF-negative thyroid carcinomas in Indonesia.
    Heriyanto DS; Laiman V; Limantara NV; Anantawikrama WP; Yuliani FS; Cempaka R; Anwar SL
    BMC Res Notes; 2022 Dec; 15(1):369. PubMed ID: 36510281
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Driver Mutation Analysis and PD-L1 Expression in Synchronous Double Primary Lung Cancer.
    Jia X; Zhang L; Wu W; Zhang W; Wu C
    Appl Immunohistochem Mol Morphol; 2018 Apr; 26(4):246-253. PubMed ID: 27438512
    [TBL] [Abstract][Full Text] [Related]  

  • 76. EGFR fluorescence in situ hybridization-positive lung adenocarcinoma: incidence of coexisting KRAS and BRAF mutations.
    Chiosea S; Shuai Y; Cieply K; Nikiforova MN; Dacic S
    Hum Pathol; 2010 Aug; 41(8):1053-60. PubMed ID: 20381121
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Correlation of EGFR or KRAS mutation status with 18F-FDG uptake on PET-CT scan in lung adenocarcinoma.
    Takamochi K; Mogushi K; Kawaji H; Imashimizu K; Fukui M; Oh S; Itoh M; Hayashizaki Y; Ko W; Akeboshi M; Suzuki K
    PLoS One; 2017; 12(4):e0175622. PubMed ID: 28422979
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Molecular Signatures of
    Hsu J; Annunziata JF; Burns E; Bernicker EH; Olsen RJ; Thomas JS
    Clin Pathol; 2022; 15():2632010X221102054. PubMed ID: 35634237
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Somatic mutations and immune checkpoint biomarkers.
    Parris BA; Shaw E; Pang B; Soong R; Fong K; Soo RA
    Respirology; 2019 Mar; 24(3):215-226. PubMed ID: 30636374
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Distribution and prognostic impact of EGFR and KRAS mutations according to histological subtype and tumor invasion status in pTis-3N0M0 lung adenocarcinoma.
    Ito M; Miyata Y; Kushitani K; Ueda D; Takeshima Y; Okada M
    BMC Cancer; 2023 Mar; 23(1):248. PubMed ID: 36918771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.